Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Research Article

An Eight-year, Single-center Experience on Ultrasound Assisted Thrombolysis with Moderate-dose, Slow-infusion Regimen in Pulmonary Embolism

Author(s): Cihangir Kaymaz*, Ozgur Yasar Akbal, Berhan Keskin, Hacer Ceren Tokgoz, Aykun Hakgor, Ali Karagoz, Seda Tanyeri, Barkın Kultursay, Seyhmus Kulahcioglu, Cem Dogan, Zubeyde Bayram, Süleyman Çağan Efe, Atakan Erkılınç, Ibrahim Halil Tanboga, Mehmet Akbulut, Nihal Ozdemir, Victor Tapson and Stavros Konstantinides

Volume 20, Issue 4, 2022

Published on: 31 May, 2022

Page: [370 - 378] Pages: 9

DOI: 10.2174/1570161120666220428095705

Price: $65

Abstract

Background: There is limited data on moderate-dose with slow-infusion thrombolytic regimen by ultrasound-asssisted-thrombolysis (USAT) in patients with acute pulmonary embolism (PE).

Aims: In this study, our eight-year experience on USAT with moderate-dose, slow-infusion tissue-type plasminogen activator (t-PA) regimen in patients with PE at intermediate-high- and high-risk was presented, and short-, and long-term effectiveness and safety outcomes were evaluated.

Methods: Our study is based on the retrospective evaluation of 225 patients with PE having multiple comorbidities who underwent USAT.

Results: High- and intermediate-high-risk were noted in 14.7% and in 85.3% of patients, respectively. Mean t-PA dosage was 35.4±13.3 mg, and the infusion duration was 26.6±7.7 h. Measures of pulmonary artery (PA) obstruction and right ventricle (RV) dysfunction were improved within days (p<0.0001 for all). During the hospital stay, major and minor bleeding and mortality rates were 6.2%, 12.4%, and 6.2%, respectively. Bleeding and unresolved PE accounted for 50% and 42.8% of in-hospital mortality, respectively. Age, rate, and duration of t-PA were not associated with in-hospital major bleeding and mortality. Oxygen saturation exceeded 90% in 91.2% of patients at discharge. During follow-up of median 962 (610-1894) days, high-risk status related to 30-day mortality, whereas age >65 years was associated with long-term mortality.

Conclusion: Our real-life experience with USAT with moderate-dose, slow-infusion t-PA regimen in patients with PE at high-and intermediate-high risk demonstrated clinically relevant improvements in PA obstructive burden and RV dysfunction. Age, rate or infusion duration of t-PA was not related to major bleeding or mortality risk, whereas unresolved obstruction remained as a lethal issue.

Keywords: Ultrasound assisted thrombolysis, catheter directed thrombolysis, pulmonary embolism, bleeding, mortality, tissue plasminogen activator.

Graphical Abstract

[1]
Konstantinides SV, Torbicki A, Agnelli G, et al. Task force for the diagnosis and management of acute pulmonary embolism of the european society of cardiology (ESC) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35(43) 3033-3069, 3069a-3069k.
[http://dx.doi.org/10.1093/eurheartj/ehu283] [PMID: 25173341]
[2]
Konstantinides SV, Meyer G, Becattini C, et al. The task force for the diagnosis and management of acute pulmonary embolism of the european society of cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J 2019; 54(3): 1901647.
[http://dx.doi.org/10.1183/13993003.01647-2019] [PMID: 31473594]
[3]
Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: A systematic review and meta-analysis. Eur Heart J 2019; 40(11): 902-10.
[http://dx.doi.org/10.1093/eurheartj/ehy873] [PMID: 30590531]
[4]
Barco S, Vicaut E, Klok FA, Lankeit M, Meyer G, Konstantinides SV. PEITHO Investigators. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: Implications for future trials. Eur Respir J 2018; 51(1): 1701775.
[http://dx.doi.org/10.1183/13993003.01775-2017] [PMID: 29348184]
[5]
Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA 2014; 311(23): 2414-21.
[http://dx.doi.org/10.1001/jama.2014.5990] [PMID: 24938564]
[6]
Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: A systematic review and meta-analysis. Eur Heart J 2015; 36(10): 605-14.
[http://dx.doi.org/10.1093/eurheartj/ehu218] [PMID: 24917641]
[7]
Greenfield LJ, Bruce TA, Nichols NB. Transvenous pulmonary embolectomy by catheter device. Ann Surg 1971; 174(6): 881-6.
[http://dx.doi.org/10.1097/00000658-197112000-00001] [PMID: 5132432]
[8]
Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: Systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20(11): 1431-40.
[http://dx.doi.org/10.1016/j.jvir.2009.08.002] [PMID: 19875060]
[9]
Kuo WT, Banerjee A, Kim PS, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT): Initial results from a prospective multicenter registry. Chest 2015; 148(3): 667-73.
[http://dx.doi.org/10.1378/chest.15-0119] [PMID: 25856269]
[10]
Konstantinides SV, Barco S. Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques. Thromb Res 2017; 164: 163-9.
[11]
Dumantepe M, Uyar I, Teymen B, Ugur O, Enc Y. Improvements in pulmonary artery pressure and right ventricular function after ultra-sound-accelerated catheter-directed thrombolysis for the treatment of pulmonary embolism. J Card Surg 2014; 29(4): 455-63.
[http://dx.doi.org/10.1111/jocs.12354] [PMID: 24827636]
[12]
Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129(4): 479-86.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005544] [PMID: 24226805]
[13]
Engelberger RP, Moschovitis A, Fahrni J, et al. Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism. Eur Heart J 2015; 36(10): 597-604.
[http://dx.doi.org/10.1093/eurheartj/eht531] [PMID: 24334719]
[14]
Piazza G, Hohlfelder B, Jaff MR, et al. SEATTLE II Investigators. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv 2015; 8(10): 1382-92.
[http://dx.doi.org/10.1016/j.jcin.2015.04.020] [PMID: 26315743]
[15]
Ozcinar E, Cakici M, Dikmen Yaman N, et al. Thrombus resolution and right ventricular functional recovery using ultrasound-accelerated thrombolysis in acute massive and submassive pulmonary embolism. Int Angiol 2017; 36(5): 428-37.
[http://dx.doi.org/10.23736/S0392-9590.17.03775-0] [PMID: 28206731]
[16]
Kaymaz C, Öztürk S, Akbal Ö, et al. Ultrasound-Assisted catheter-directed thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: Results from a single-center cohort. Angiology 2017; 68(5): 433-40.
[http://dx.doi.org/10.1177/0003319716661446] [PMID: 27485362]
[17]
Kaymaz C, Akbal OY, Hakgor A, et al. A five-year, single-centre experience on ultrasound-assisted, catheter-directed thrombolysis in patients with pulmonary embolism at high risk and intermediate to high risk. EuroIntervention 2018; 14(10): 1136-43.
[http://dx.doi.org/10.4244/EIJ-D-18-00371] [PMID: 30082262]
[18]
Kaymaz C, Akbal ÖY, Tanboğa IH, et al. Ultrasound-Assisted catheter-directed thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: A meta-analysis. Curr Vasc Pharmacol 2018; 16(2): 179-89.
[http://dx.doi.org/10.2174/1570161115666170404122535] [PMID: 28393706]
[19]
Giri J, Sista AK, Weinberg I, et al. Interventional therapies for acute pulmonary embolism: Current status and principles for the development of novel evidence: A scientific statement from the american heart association. Circulation 2019; 140(20): e774-801.
[http://dx.doi.org/10.1161/CIR.0000000000000707] [PMID: 31585051]
[20]
Pei DT, Liu J, Yaqoob M, et al. Meta-Analysis of catheter directed ultrasound-assisted thrombolysis in pulmonary embolism. Am J Cardiol 2019; 124(9): 1470-7.
[http://dx.doi.org/10.1016/j.amjcard.2019.07.040] [PMID: 31492420]
[21]
Rao G, Xu H, Wang JJ, et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: A multi-center comparison of patient-centered outcomes. Vasc Med 2019; 24(3): 241-7.
[http://dx.doi.org/10.1177/1358863X19838334] [PMID: 30915914]
[22]
Tapson VF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: The OPTALYSE PE trial. JACC Cardiovasc Interv 2018; 11(14): 1401-10.
[http://dx.doi.org/10.1016/j.jcin.2018.04.008] [PMID: 30025734]
[23]
Piazza G, Sterling KM, Tapson VF, et al. One-Year echocardiographic, functional, and quality of life outcomes after ultrasound-facilitated catheter-based fibrinolysis for pulmonary embolism. Circ Cardiovasc Interv 2020; 13(8): e009012.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009012] [PMID: 32757658]
[24]
Qanadli SD, El Hajjam M, Vieillard-Baron A, et al. New CT index to quantify arterial obstruction in pulmonary embolism: Comparison with angiographic index and echocardiography. AJR Am J Roentgenol 2001; 176(6): 1415-20.
[http://dx.doi.org/10.2214/ajr.176.6.1761415] [PMID: 11373204]
[25]
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8(1): 202-4.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03678.x] [PMID: 19878532]
[26]
Dattilo G, Falanga G, Casale M, et al. Oral anticoagulants: Old and new therapy. Adv Med Biol 2015; 83: 13-71.
[27]
Imbalzano E, Creazzo M, Trapani G, et al. Heparin: Structure, Drug Delivery Applications and Clinical Outcomes. In: Wilkinson NB, Ed. Heparin: Which Molecule? What Clinical Applications. (1st ed..). Nova press 2014; pp. 1-20.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy